Effects of Melissa officinalis (Lemon Balm) on cardio-metabolic outcomes: A systematic review and meta-analysis

Heshmati, J. and Morvaridzadeh, M. and Sepidarkish, M. and Fazelian, S. and Rahimlou, M. and Omidi, A. and Palmowski, A. and Asadi, A. and Shidfar, F. (2020) Effects of Melissa officinalis (Lemon Balm) on cardio-metabolic outcomes: A systematic review and meta-analysis. Phytotherapy Research, 34 (12). pp. 3113-3123.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....


Recent evidence indicates a beneficial effect of Melissa officinalis (MO) intake on several chronic diseases. However, the effects of MO intake have not yet been systematically reviewed. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the effect of MO intake and focused on several cardiometabolic outcomes. MEDLINE, Scopus, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials were searched for MO-RCTs evaluating cardiometabolic outcomes. Random-effects meta-analyses estimated the pooled standardized mean differences (SMD) between intervention and control groups. Risk of bias was assessed with the Cochrane Collaboration's tool for assessing the risk of bias in RCTs. Seven RCTs were finally deemed eligible. MO intake was associated with a reduced total cholesterol (TC) (SMD: �0.26; 95 CI: �0.52, �0.01; I2 = 13.7; k = 6) and a reduced systolic blood pressure (SBP) (SMD: �0.56; 95 CI: �0.85, �0.27; I2 = 00.0; k = 3). MO intake was not associated with statistically significant changes in triglycerides, low-density lipoprotein, diastolic blood pressure, high sensitivity c-reactive protein levels, fasting blood sugar, HbA1c, insulin or high-density lipoprotein levels. No serious adverse events were reported. The risk of bias was high in a considerable amount of studies. Our study suggests that MO is a safe supplement with beneficial effects on TC and SBP. However, the findings of our study must be seen in the light of major limitations such as a low number of included studies and a serious risk of bias. High-quality RCTs are needed for firm conclusions concerning the effects of MO on cardiometabolic outcomes. © 2020 John Wiley & Sons, Ltd.

Item Type: Article
Additional Information: cited By 2
Uncontrolled Keywords: C reactive protein; cholesterol; glucose; hemoglobin A1c; high density lipoprotein cholesterol; insulin; low density lipoprotein cholesterol; triacylglycerol; plant extract, adverse event; cardiometabolic risk; cholesterol blood level; clinical effectiveness; clinical evaluation; clinical outcome; disease association; human; inflammation; insulin blood level; lipid fingerprinting; Melissa officinalis; meta analysis; protein blood level; Review; risk assessment; systematic review; systolic blood pressure; triacylglycerol blood level; cardiovascular disease; chemistry; chronic disease; dietary supplement; metabolic disorder; physiology; phytotherapy; randomized controlled trial (topic); treatment outcome, Cardiovascular Diseases; Chronic Disease; Dietary Supplements; Humans; Melissa; Metabolic Diseases; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Treatment Outcome
Subjects: WB Practice of Medicine
WG Cardiovascular System
Depositing User: eprints admin
Date Deposited: 16 May 2021 09:32
Last Modified: 16 May 2021 09:32
URI: http://eprints.iums.ac.ir/id/eprint/33661

Actions (login required)

View Item View Item